Semaglutide attenuates myocardial ischemia-reperfusion injury by inhibiting ferroptosis of cardiomyocytes via activation of PKC-S100A9 axis

Yan Liu, Zixuan Li, Xiaomeng Xu, Yan Zou, Miaomiao Zhang, Yingyu Chen, Wenwu Zhu, Bing HanFrontiers in Pharmacology 2025 · DOI

Abstract

Semaglutide can reduce I/R-induced myocardial injury by inhibiting the ferroptosis of cardiomyocytes. In the mechanism, semaglutide mainly reduce the expression of S100A9 via the activation of PKC signaling pathway. Therefore, semaglutide is considered as a potential treatment option for MIRI.

Introduction

Myocardial Ischemia-Reperfusion Injury (MIRI) remains a significant clinical challenge in cardiology. While restoring blood flow is essential after a heart attack, the subsequent reperfusion often triggers secondary damage, leading to permanent scarring (fibrosis) and heart failure. Recent evidence highlights ferroptosis—an iron-dependent form of regulated cell death driven by lipid peroxidation—as a critical driver of this injury. This study investigates whether semaglutide, a popular GLP-1 receptor agonist, can mitigate MIRI by directly targeting the ferroptotic process.

Methodology

The researchers employed a multi-scale approach to evaluate semaglutide's efficacy:

  • Animal Model: C57BL/6J mice underwent 45 minutes of left anterior descending (LAD) coronary artery ligation followed by 24 hours of reperfusion. Semaglutide (0.6 mg/kg) was administered weekly for four weeks prior to injury.
  • Cellular Model: HL-1 cardiomyocytes were subjected to Hypoxia/Reoxygenation (H/R) to simulate MIRI conditions in vitro.
  • Analysis: The team used RNA-sequencing (GSA accession CRA023327E) to identify gene expression changes. Heart function was assessed via echocardiography, while mitochondrial damage was observed using Transmission Electron Microscopy (TEM). Ferroptosis was quantified through levels of ferrous iron ($Fe^{2+}$), malondialdehyde (MDA), and the antioxidant enzyme GPX4.

The PKC-S100A9 Signaling Pathway

A central finding of this research is the identification of the PKC-S100A9 axis as the primary mechanism for semaglutide's cardioprotective effects. RNA-seq and Gene Set Enrichment Analysis (GSEA) revealed that semaglutide activates the Protein Kinase C (PKC) signaling pathway, which in turn suppresses the expression of S100A9, a pro-inflammatory calcium-binding protein associated with tissue injury.

Graphical abstract illustrating the mechanism of semaglutide in reducing ferroptosis and promoting cardiac repair.

By inhibiting S100A9, semaglutide effectively reduces the biochemical markers of ferroptosis, such as lipid damage and iron accumulation, while upregulating the protective enzyme GPX4. This pathway directly shields cardiomyocytes from the oxidative stress triggered during reperfusion.

Key Results

  • Improved Cardiac Function: Mice treated with semaglutide showed significantly higher Left Ventricular Ejection Fraction (LVEF) and Shortening Fraction (LVFS) compared to untreated MIRI controls.
  • Structural Protection: Semaglutide treatment led to a marked reduction in infarct size (the area of dead heart tissue) and preserved mitochondrial morphology, preventing the characteristic shrinkage seen in ferroptotic cells.
  • Reduced Fibrosis: 14 days post-injury, the semaglutide-treated group exhibited substantially less collagen deposition, indicating reduced long-term scarring.

Conclusion and Future Directions

This study demonstrates that semaglutide's cardiovascular benefits extend beyond metabolic control; it directly protects cardiomyocytes from MIRI-induced ferroptosis via the PKC-S100A9 axis. However, because the study utilized a four-week pre-treatment regimen, future research must determine if semaglutide is effective as an acute intervention during or after a heart attack. Additionally, clinical trials in non-diabetic human populations are necessary to confirm the translational potential of these findings.

Summary updated

Abstract

Semaglutide can reduce I/R-induced myocardial injury by inhibiting the ferroptosis of cardiomyocytes. In the mechanism, semaglutide mainly reduce the expression of S100A9 via the activation of PKC signaling pathway. Therefore, semaglutide is considered as a potential treatment option for MIRI.
BibTeX
@inproceedings{liu2025semaglutide,
  author = {Yan Liu and Zixuan Li and Xiaomeng Xu and Yan Zou and Miaomiao Zhang and Yingyu Chen and Wenwu Zhu and Bing Han},
  title = {{Semaglutide attenuates myocardial ischemia-reperfusion injury by inhibiting ferroptosis of cardiomyocytes via activation of PKC-S100A9 axis}},
  booktitle = {Frontiers in Pharmacology},
  year = {2025},
  doi = {10.3389/fphar.2025.1529652},
}
Figure